Tempest TherapeuticsTPST -0.36%32 EV-to-EBIT is -0.51 as of Jul. 09, 2026. GuruFocus rates TPST with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 366 Biotechnology companies, Tempest Therapeutics ranks worse than 273223.77% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Tempest Therapeutics's Enterprise Value for the quarter that ended in Mar. 2026 was $29.57 Mil.
Tempest Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-43.05 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tempest Therapeutics EV-to-EBIT Related Terms
Tempest Therapeutics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Tempest Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Tempest Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tempest Therapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tempest Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Tempest Therapeutics's EV-to-EBIT falls into.
Tempest Therapeutics's current Enterprise Value is $21.77 Mil.
Tempest Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-43.05 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tempest Therapeutics (TPST) has a EV-to-EBIT of -0.51 as of Jul. 09, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Tempest Therapeutics and its competitors. According to the industry distribution chart, Tempest Therapeutics ranks #999999 out of 366 companies in the Biotechnology industry.
Is Tempest Therapeutics' EV-to-EBIT too high?
Tempest Therapeutics' current EV-to-EBIT is -0.51. Based on the distribution chart, Tempest Therapeutics ranks #999999 out of 366 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tempest Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Tempest Therapeutics' EV-to-EBIT compare to HOWL and INTI?
According to the Biotechnology industry distribution chart, Tempest Therapeutics ranks #999999 out of 366 companies for EV-to-EBIT. This places Tempest Therapeutics in the lower half of its industry. The industry median EV-to-EBIT is 14.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 14.63, based on 366 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Tempest Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 14.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tempest Therapeutics's current EV-to-EBIT is -0.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tempest Therapeutics stock overvalued right now?
Tempest Therapeutics (TPST) has a current EV-to-EBIT of -0.51. The current EV-to-EBIT is -0.51. Tempest Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Tempest Therapeutics (TPST), the current EV-to-EBIT is -0.51 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
32GF Score
Get the complete analysis for TPST
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPST has been successfully added to your 
